Objective: To ensure the health of newborns, it is necessary to perform high-quality diagnostic tests. The TORCH panel is a set of tests that identifies infectious pathogens such as Toxoplasma (Toxo) and Cytomegalovirus (CMV) that are common in low-setting populations. We performed TORCH panel quality planning using six sigma in a reference laboratory at Peru.

Results: This was a cross-sectional study. TORCH tests include Toxo, Rubella, CMV, and Herpes. We processed all samples by fourth-generation ELISA on the GEMINI XCR200 analyzer (Diatron, Budapest, Hungary). We obtained the imprecision from the annual data of the external quality assessment plan and we used the CLSI EP12-A3 guideline. In a total of 44,788 analyses, the average imprecision was 3.69 ± 1.47%, and CMV had lower imprecision (2.3 and 2.6% for IgM and IgG, respectively). Quality planning of the TORCH panel allowed estimating the sigma value that ranged from 4 to 10 (average 7 ± 2 sigma), where rubella had the highest values (10 for IgM and 8 for IgG) while HSV2 had the lowest values (4 for IgM and 5 for IgG). Our results suggest the optimal performance of half of the markers including Toxoplasma, Rubella, and CMV in the Peruvian population.

Keywords: Six sigma, Toxoplasma, Quality assurance, Cytomegalovirus, Quality management, Enzyme-linked immunosorbent assay

Introduction

One of the main threats to neonatal and child health is the high rates of infections that cause 1.2 million deaths each year [1]. Therefore, one of the main guidelines of the Sustainable Development Goals for 2030 is to ensure neonatal health worldwide [2]. Consequently, it is necessary to prevent infectious diseases, one of the most frequent diseases affecting the children and neonates by improving detection and follow-up systems.

Globally, perinatal management is crucial to reduce neonatal morbidity and mortality levels, mainly in low-income settings where sepsis is a common complication and infectious diseases reach their peak [3]. TORCH tests, an immunological screening panel to detect the main infectious agents associated with neonatal diseases, are used to diagnose infections [4]. The TORCH panel can be performed with immunological methods such as immunochromatography, enzyme-linked immunosorbent assay (ELISA) or chemiluminescence immunoassay (CLIA) that show the presence of antibodies against TORCH infectious agents.

ELISA tests are the most widely used methods and probably have limitations since they cannot detect significant losses (analytical sensitivity) and may interfere...
with the final result causing false negatives [5]. For those reasons, it is necessary to develop verification studies and quality planning in qualitative immunological methods, estimating their suitability through the six sigma or OPSpecs charts as previously demonstrated [6–8]. In Peru, many clinical laboratories have limited access to quality management processes, performing few quality assessments in qualitative tests such as ELISA tests, despite the studies that propose quality assessment schemes for ELISA [5].

In this cross-sectional study, we aim to perform TORCH panel quality planning using six sigma in Peru. With fewer studies focusing on developing quality assessments in qualitative tests, our purpose is to know the level of performance and compliance with quality requirements.

Main text
Study design and TORCH panel
We carried out this observational cross-sectional and single-centred study at the Suiza Lab in Lima, Peru. According to the objectives of this study we used TORCH tests for Toxoplasma, Rubella, Cytomegalovirus, and Herpes (all from Diatron, Budapest, Hungary). For all infectious markers, IgG and IgM were determined. Following the manufacturer’s specifications, the GEMINI XCR200 automated kit (Diatron, Budapest, Hungary) processed the samples by a fourth-generation qualitative ELISA. This equipment has a photometric reading range of 0–3.0 absorbance (Abs) (range 400–700 nm), an accuracy of 1% CV at 1.0 Abs, and linearity of 0–2000 Abs. The incubator features an integral wash system with a capacity of three washes and an accuracy of 10% CV at 300 μl.

Quality analytic requirements
For each enzyme-linked immunosorbent assay, we verified calibration using linearity as previously described [6]. Data were collected for 2019 to determine the minimum acceptable concentrations measured in Abs for each marker following previous protocols [5, 6]. We assessed the correlation between the absorbance of the samples and the cut-off for each test, following the recommendations of the CLSI EP12-A3 guideline [9]. The cut-off was the measure derived from the results of three negative calibrators plus a fixed value. From this correlation, we estimated the quality requirements for each marker.

Quality planning and data analysis
We developed quality planning according to the previous steps of defining the quality requirements. The bias was not evaluated and had a value of 0 for all the TORCH panels [10]. The imprecision of each test was estimated from the annual evaluation values of the External Quality Assessment Program in which Suiza Lab participates. From these data established for each marker, the sigma value of each test was estimated using the formula:

$$\text{Sigma} = \frac{\text{Quality requirement} - \text{bias}}{\text{imprecision}}$$

The QC candidate selection procedure was performed under the Westgard rules: 12.5s, 13s, 13.5s, 22.5s, 13s/22s, 13.5s/22.5s y 13.5s/22.5s/R.4s [5, 11]. The sigma metric analysis was created in SPSS version 25.0 (IBM, Armonk, USA) for Windows. The estimation of the statistical control rules according to the sigma value was performed using the sigma charts following previous recommendations [12]. This selection was developed considering the best fit for the probability of error detection (Ped) and the probability of false rejection (Pfr) of each TORCH’s panel marker.

Results
We developed the quality planning for eight TORCH panel markers [Toxoplasma gondii (Toxo), Rubella, Cytomegalovirus (CMV) and Herpes Virus 1 (HSV1) and HSV2], and a total of 44,788 analyses were reviewed. The minimum acceptable concentration was obtained, finding an average of 20.8±7.4% for the quality requirements for each marker.

The imprecision analysis was assessed by intra-assay CV% for each infectious marker. In addition, an average imprecision of 3.69±1.47% was found. Our results indicate that CMV had lower imprecision (2.3% for IgM and 2.6% for IgG) while Toxo had a 5% imprecision and 5.38% for Toxo IgM and IgG, respectively.

Quality planning of the TORCH panel allowed estimating the sigma value that ranged from 4 to 10, where rubella had the highest values (10 for IgM and 8 for IgG) while HSV2 had the lowest values (4 for IgM and 5 for IgG). These results appear in Table 1. Fifty percent of the tests had a sigma greater than 6 (average 7 ± 2 sigma).

The results shown in Fig. 1 reveal the selected control rules for the TORCH markers. For the two rubella markers, IgM of Toxo and CMV, and IgG of HSV1, control multi-rules were chosen as 13s/22s that provided a 100% probability of detecting a critical loss of assay sensitivity (Pfr = 0.01). On the other hand, the IgM marker of HSV1 and HSV2 required a stricter multi-rule as 13s/22s/R.4s (Ped = 1 and Pfr = 0.03) to remain in control. None of the sigmas found invalidated the use of TORCH markers. The rule selection process is in Fig. 2.

Discussion
This study of quality planning in qualitative tests suggest that 50% of markers from the TORCH panel had an optimal sigma (> 6) allow the selection and application of Westgard control rules in a reference laboratory in Peru.
The strengths of this study lie in being one of the first studies to apply the sigma metric to qualitative TORCH tests in Latin America. Also, this study used a qualitative test analysis algorithm that demonstrated an optimal level of sigma performance of the TORCH panel. Knowing the efficiency of these markers is crucial to ensure neonatal health.

In order to control a test, it is necessary to apply statistical control methods that allow the test to be maintained within typical values and to be able to demonstrate the alterations that diseases demand. Although this is the goal of quality control processes, planning is the pillar to organize all processes and ensure the quality of results [13, 14]. Modern practical concepts within analytical quality planning include using sigma metrics as a widely applicable method with a fast and simple calculation to organize quality axes in daily clinical practice.

Our findings demonstrated excellent performance for Rubella (> 6 sigma) and good performance for Toxo and CMV (5–< 6 sigma). These sigma results are substantially higher compared to two studies on thyroid hormones in the Indian population and transfusion viral infectious markers in the Mexican population that reported a sigma of < 3 and < 4, respectively [7, 8]. We recently demonstrated following the same algorithm optimal sigma in 2/7 infectious markers in a Peruvian blood bank [5]. Both previous results indicate the suitability of this quality planning method for qualitative tests.

Six sigma has demonstrated efficiency in the assessment of clinical laboratory assays using software or manually with multiple institutional benefits [15–17]. In low-income settings laboratories, the implementation of efficient quality programs is so necessary because in Peru [18], several public and private laboratories work daily without establishing their quality limits, putting at risk medical decisions based on clinical analysis.

Although laboratory medicine has been transcendental for Peruvian medicine [19], there is no organized program for global quality assurance. Even the National Institute of Quality (INACAL) does not ensure the standardization of its tests. Therefore, the overall quality of the results issued is still unknown. Evaluations

---

**Table 1** Baseline results for the TORCH panel tests evaluated with the sigma metric

| TORCH panel                  | Abs | Cutt-off | Quality requirements<sup>a</sup> | Imprecision<sup>b</sup> | Sigma | ΔSE |
|------------------------------|-----|----------|----------------------------------|-------------------------|-------|-----|
| Toxoplasma gondii            |     |          |                                  |                         |       |     |
| IgM                          | 0.007| 0.005    | 28.6                             | 5                       | 6     | 4.06|
| IgG                          | 0.012| 0.008    | 33.3                             | 6.2                     | 5     | 3.73|
| Rubella                      |     |          |                                  |                         |       |     |
| IgM                          | 0.027| 0.02     | 25.9                             | 2.6                     | 10    | 8.35|
| IgG                          | 0.219| 0.177    | 19.2                             | 2.4                     | 8     | 6.35|
| Cytomegalovirus              |     |          |                                  |                         |       |     |
| IgM                          | 0.054| 0.047    | 13                               | 2.3                     | 6     | 3.99|
| IgG                          | 0.022| 0.019    | 13.6                             | 2.6                     | 5     | 3.59|
| Herpes simplex virus 1       |     |          |                                  |                         |       |     |
| IgM                          | 0.084| 0.074    | 11.9                             | 3                       | 4     | 2.32|
| IgG                          | 0.023| 0.019    | 17.4                             | 2.7                     | 6     | 4.79|
| Herpes simplex virus 2       |     |          |                                  |                         |       |     |
| IgM                          | 0.055| 0.045    | 18.2                             | 4.6                     | 4     | 2.30|
| IgG                          | 0.015| 0.011    | 26.7                             | 5.5                     | 5     | 3.20|

<sup>a</sup> In %  
<sup>b</sup> In %CV

---

**Fig. 1** Westgard rules selected for TORCH panel control. For both IgM and IgG, sigma greater than 6 (blue box), sigma of 6 (green box) and sigma between 4 and 5 (yellow box) are shown.

---
under sigma metrics have an increasing impact on qualitative tests as a result of the studies and models that have gradually emerged in the last two decades [20]. Further studies are needed to scrutinize the quality assurance processes using sigma metrics in qualitative tests.

In this study, the selection of control rules has been multi-rule as it is set out with a high Ped to assess both systematic and random error. We have been most insidious with markers of sigmas of 4 for IgM of HSV1 and HSV2. Quality control, including the frequency of control and validation processes, the maintenance of equipment and staff training and participation in external and internal quality control programs are necessary to keep these markers within quality standards [14, 20, 21].

**Conclusion**

Quality planning of the TORCH panel in the Peruvian population demonstrated optimal performance of half of the markers, including Toxoplasma, Rubella and CMV. Using six sigma multi-rule controls were selected for HSV1 and HSV2 that had 4–5 sigma to maintain quality. This study continues the roadmap for quality assurance of qualitative tests used in the clinical laboratory as routine tests; the development of quality planning processes for qualitative tests should be a commitment for all health care institutions.

**Limitation**

The performance and sigma value of the TORCH panel could be affected by intra and inter-individual variations in the study subjects as the prevalence of infectious markers and the kind of users of the Suiza Lab in Lima, Peru. In addition, this quality planning was conducted on fourth-generation GEMINI XCR200 ELISA automated equipment; however, performance could vary with the CLIA test. Finally, due to its cross-sectional design, it was impossible to establish causal relationships between the sigma values of panel performance with some process features (i.e., pre-analytical errors, calibration frequency, participation in external quality programs).

**Abbreviations**

TORCH: Toxoplasmosis, other infections, Rubella, Cytomegalovirus, and Herpes simplex virus; ELISA: Enzyme linked immunosorbent assay; CLIA: Chemiluminescence immunoassay; Toxo: Toxoplasma; CMV: Cytomegalovirus; HSV1: Herpes simple virus 1; HSV2: Herpes simple virus 2; Ped: Probabilidad de detección de error; Pfr: Probabilidad de falso rechazo.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

JMS: study conception, study design, sample collection and analysis, data analysis, article writing, approval of the final version. BMS: sample collection and analysis, article writing, approval of the final version. MMMS: data analysis, article writing, approval of the final version. VRZ: study design, article writing, final version approval. KCF: data analysis, article writing, approval of the final version. HCP: study design, data analysis, article writing, final version approval. All authors read and approved the final manuscript.
Funding
Self-Funding by the authors.

Availability of data and materials
None.

Declarations

Ethics approval and consent to participate
None.

Consent for publication
Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1. Department of Pathology, Hospital Nacional Docente Madre-Niño San Bartolomé, Lima, Peru. 2. Faculties of Health Science, School of Medicine, Universidad Norbert Wiener, 444 Arequipa Av., S1001 Lima, Peru. 3. Faculties of Health Science, School of Medical Technology, Universidad Norbert Wiener, Lima, Peru. 4. Clinical and Laboratory Department, Suiza Lab, Lima, Peru. 5. Faculty of Pharmacy and Biochemistry, Universidad Norbert Wiener, Lima, Peru. 6. South America Center for Education and Research in Public Health, Universidad Norbert Wiener, Lima, Peru.

Received: 18 September 2021   Accepted: 31 December 2021
Published online: 11 January 2022

References

1. Fleischmann-Struwe C, Goldfarb DM, Schlattmann P, Schlapbach LJ, Reinhardt K, Kissoon N. The global burden of paediatric and neonatal sepsis: a systematic review. Lancet Respir Med. 2018;6(3):223–30. https://doi.org/10.1016/S2213-2600(18)30063-8.
2. United Nations. The sustainable development goals report. New York: United Nations Publications, 2016.
3. Fleischmann C, Reichert F, Cassini A, Horner R, Harder T, Markwart R, et al. Global incidence and mortality of neonatal sepsis: a systematic review and meta-analysis. Arch Dis Childhood. 2021;106:745–52.
4. Abdel-Fattah SA, Bhat A, Illanes S, Bartha JL, Carrington D. TORCH test for fetal medicine indications: only CMV is necessary in the United Kingdom. Pren Diag. 2005;25(11):1028–31.
5. Moya-Salazar J, Díaz-Rosado RF. Quality analytical planning in blood bank serological screening qualitative assays. Int Clin Pathol J. 2019;7(1):22–6.
6. Green GA, Carey RN, Westgard JO, Carter T, Shablesky L, Achord D, et al. Quality control for qualitative assays: qualitative QC procedure designed to assure analytical quality required for an ELISA of hepatitis B surface antigen. Clin Chem. 1997;43(9):1618–21.
7. Robles MÁK, Becerra LMG, Licón GGE. Cómo establecer requisitos de calidad para marcadores serológicos de HIV, VHC y HBsAg sin invalidar la utilidad clínica de los resultados en el Centro Estatal de la Transfusión Sanguínea Jalisco. Resúmenes de Trabajos Libres del XIV Congreso, 2016. Rev Mex Med Tran. 2016;9(1–2):3–61.
8. Modi N, Gamit D. Quality assurance in thyroid profile with the six sigma matrix. Int J Res Med. 2017;6(4):32–5.
9. Clinical and Laboratory Standard Institute. User protocol for evaluation of qualitative test performance. CLSI document EP12-A2. Wayne: CLSI, 2008.
10. Westgard JO. Basic method validation. 1st ed. Madison: Westgard Quality Corporation; 2008.
11. Westgard JO, Groth T, Aromsson T, et al. Performance characteristics of control rules for internal quality control: probabilities for false rejection and error detection. Clin Chem. 1997;23(10):1857–67.
12. Westgard JO, Steen B. An automated process for selecting statistical QC procedures to assure clinical and analytical quality requirements. Clin Chem. 1997;43(4):400–3.
13. CLIA. Clinical Laboratory Improvement Act of 1988; Final Rule. Fed Reg. 1992;57:7164.
14. Westgard JO. Planning and validating QC procedures: workshop manual. 2nd ed. Washington, DC: Amer Assn for Clinical Chemistry; 1997.
15. Westgard JO, Steen B, Westgard SA, Kennedy R. QC Validator 2.0: a computer program for automatic selection of statistical QC procedures for applications in healthcare laboratories. Comput Methods Programs Biomed. 1997;53(3):175–86.
16. Liu Q, Chen X, Han J, Chen Y, Wang M, Zhao J, Liang W, Yang F. Application of a six-sigma model to the evaluation of the analytical performance of serum enzyme assays and the design of a quality control strategy for these assays: a multicentre study. Clin Biochem. 2021;91:52–8.
17. Chakraborty A, Chuan TK. Qualitative and quantitative analysis of six sigma in Service Organizations. London: IntechOpen; 2012.
18. Moya-Salazar J, Pio-Davila L. Evaluation of inter-batch variability in establishing and quality control of glucose. Med Univ. 2016;18(71):85–90.
19. Colegio Medico del Perú. Libro del bicentenario de la independencia nacional 1821–2021. Lima. Arte Perú S.A.C, 2021.
20. Westgard S, Bayat H, Westgard JO. Analytical Sigma metrics: a review of Six Sigma implementation tools for medical laboratories. Biochem Med. 2018;28(2):020502.
21. Zaman G. Quality control in laboratory. London: IntechOpen, 2018.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.